Racura Oncology

Directions Website Contact the business

Racura Oncology Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a mission to silence cancer

03/11/2026

Women's health is an increasingly important frontier for healthcare innovation, with advances in cancer care creating opportunities to improve quality of life for patients across the world.

In a recent feature by BioSpectrum Asia, Racura Oncology CEO & Managing Director Dr Daniel Tillett shares his perspectives on the evolving landscape of women's cancer care, including the importance of addressing the longer-term side effects of current standard of care cancer treatments.

Racura is exploring this through trials of our lead asset RC220, investigating its anticancer potential across multiple indications, as well as its ability to protect against chemotherapy-induced heart damage.

Read the full article: https://www.biospectrumasia.com/analysis/29/28623/rewriting-the-future-of-womens-health.html

27/10/2026

Racura Oncology CEO & Managing Director Dr Daniel Tillett has been featured in Stockhead’s analysis of the interconnected “family tree” of ASX healthcare leaders.

The feature explores Daniel’s biotech journey - from founding Nucleics, to his contributions to Entropy Neurodynamics, TrivarX, and Island Pharmaceuticals, in addition to his CEO role at Racura.

Daniel also shares his perspective on the relative merits of cross-fertilisation across the sector, and why shared common experiences can make navigating challenges easier to manage.

Read the full feature in Stockhead: https://stockhead.com.au/health/the-leaders-branching-across-the-asx-healthcare-family-tree/

We’re hiring - Racura Oncology is seeking a dedicated and highly organised Laboratory Technician to join our team based ...
23/10/2026

We’re hiring - Racura Oncology is seeking a dedicated and highly organised Laboratory Technician to join our team based within the University of Wollongong research precinct.

In this hands-on role, you will support a broad range of preclinical and clinical research operations, including clinical trial kit production, bioanalytical studies, sample processing, and biorepository management.

What we’re looking for:
• Bachelor’s degree in Science, Biomedical Science, Medical Science, Biotechnology, or a related discipline
• High attention to detail and strong organisational skills
• Ability to follow documented procedures and maintain precise records
• Excellent collaborative and communication skills

If you're passionate about contributing to innovative cancer therapies and world-class clinical research, we’d love to hear from you.

🔗Apply here: https://au.seek.com/job/95401421?ref=cm-ui

In case you missed it: Racura Executive Chair Dr Pete Smith presented at the MST Financial Biotech & Healthcare ‘New Dis...
21/10/2026

In case you missed it: Racura Executive Chair Dr Pete Smith presented at the MST Financial Biotech & Healthcare ‘New Discoveries’ webinar series last week.

Racura joined other innovative biotech and healthcare companies, providing investors with an opportunity to hear about the company’s latest corporate and clinical updates.

A recording of Racura's session is available here: https://youtu.be/azxXyPNqqXk?si=a0V8tHLLBT593d3y&t=101

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

October is Breast Cancer Awareness Month, a vital time to unite in the fight against breast cancer 🎀At Racura we are foc...
13/10/2026

October is Breast Cancer Awareness Month, a vital time to unite in the fight against breast cancer 🎀

At Racura we are focused on advancing RC220 for breast cancer patients as potent anti-cancer treatment while protecting the heart from the damage chemotherapy can cause. By shielding the heart from the side effects of traditional chemotherapy while improving the treatment of the cancer, our clinical research is aimed improving both cancer survival and long-term quality of life improvements for breast cancer patients.

We support the key message from the (National Breast Cancer Foundation) - “Research gives more people the chance to finish their story”.

To learn more about the fight against breast cancer, visit the link in the comments ⬇️

Racura Oncology is pleased to announce that the Safety Review Committee has cleared RC220 to move to the next planned do...
11/10/2026

Racura Oncology is pleased to announce that the Safety Review Committee has cleared RC220 to move to the next planned dose level of 100 mg/m² in our Phase 1 HARNESS-1 clinical trial, which is evaluating the safety and tolerability of RC220 in combination with osmertinib in patients with EGFR-mutant non-small cell lung cancer, an area of significant unmet medical need.

Dr Daniel Tillett, Racura CEO, said: “We are pleased with the SRC’s clearance, which allows RC220 to progress to the next dose level in the HARNESS-1 trial. This is an important early milestone for the trial and reflects the disciplined ex*****on of our clinical development plan.

The Cohort 1 safety review identified no dose-limiting toxicities or treatment-related safety concerns in either patient during the safety observation period. We thank the patients and their families for supporting this study and acknowledge Principal Investigator A/Prof Surein Arulananda and the Monash Health team for their ongoing contribution.”

Read the full announcement here: https://announcements.racuraoncology.com/announcements/7781266

Racura was honoured to present at the Global Cardio-Oncology Summit (GCOS) 2026 in Virginia, USA this week. GCOS is an a...
06/10/2026

Racura was honoured to present at the Global Cardio-Oncology Summit (GCOS) 2026 in Virginia, USA this week. GCOS is an annual event dedicated to advancing the prevention and management of cardiovascular disease among cancer survivors.

Racura's poster presentation provided a clinical update on our Cardioprotection & Anticancer Synergy (CPACS) Phase 1 study of RC220 in combination with doxorubicin in patients with advanced solid tumours.

CEO and Managing Director, Dr Daniel Tillett, commented: “Presenting our CPACS clinical study at the Global Cardio-Oncology Summit highlights the growing interest in RC220’s potential to address cardiotoxicity, one of the key limitations of anthracycline-based cancer therapy, while also improving anticancer treatments.”

For further information and a copy of the poster presentation, please see our announcement here: https://announcements.racuraoncology.com/announcements/7774247

Join Racura Oncology's Executive Chair, Dr Peter Smith, at the upcoming MST Financial Biotech & Healthcare ‘New Discover...
06/10/2026

Join Racura Oncology's Executive Chair, Dr Peter Smith, at the upcoming MST Financial Biotech & Healthcare ‘New Discoveries’ Webinar Series. This event offers investors a valuable opportunity to hear directly from innovative companies leading the way across the biotech and healthcare sectors.

During the session, Dr Peter Smith will present key updates on our strategic priorities and the progress of our three ongoing clinical trials investigating RC220 - our proprietary formulation of (E,E)-bisantrene - and its potential to target the key cancer driver, MYC. The presentation will conclude with a live investor Q&A session.

🗓️ Date: Tuesday, 13 October 2026
⏰ Time: 3:50 pm AEDT
🔗 Register: https://mstfinancial-au.zoom.us/webinar/register/WN_fo-XGNjoRiK832nYsXqEPw

It’s  ! 🫀 Cardiovascular health is the foundation of a long, active life, and saving lives shouldn't come at the cost of...
29/09/2026

It’s ! 🫀 Cardiovascular health is the foundation of a long, active life, and saving lives shouldn't come at the cost of the heart.

At Racura, we're proud to be looking into how our proprietary formulation of (E,E)-bisantrene, RC220, can deliver effective cancer treatments with crucial cardioprotective benefits in our Phase 1 CPACs trial (RC220 in solid tumours in combination with doxorubicin). Find out more about our CPACS trial here: https://racuraoncology.com/program/clinical-programs/

23/09/2026

In the final highlight from our Racura Symposium series, Chairman Dr Peter Smith discusses the strategic importance of our intellectual property portfolio and our capacity to reset the patent clock.

Learn how we are building comprehensive IP protection covering manufacturing at scale, formulation, and composition of matter, which is critical for engaging with prospective pharmaceutical partners. Securing a potential 20-year patent life for an asset entering Phase 3 clinical trials is highly unusual and, if granted, places the company in a strong position to maximise long-term value.

🎥 Watch presentation below

Address

L36, 1 Macquarie Place
Sydney, NSW
2000

Alerts

Be the first to know and let us send you an email when Racura Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Racura Oncology:

Shortcuts

Share